SS Innovations International (NASDAQ: SSII) has reported significant growth in the utilization and global reach of its SSi Mantra surgical robotic system. As of Sept. 8, 2026, the company has logged 14,103 cumulative procedures, a 79% increase from 7,885 at the end of 2025. The installed base of SSi Mantra systems has grown 42% to 238 units, up from 168. These figures underscore the accelerating adoption of robotic surgery in markets where affordability and accessibility have historically been barriers.
The SSi Mantra is now installed in 12 countries, with approximately 1,500 physicians trained on the platform. The system has been used for more than 170 types of surgical procedures, demonstrating its versatility. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the first installation of an SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the company's success in penetrating diverse healthcare markets and advancing surgical care.
SS Innovations also emphasized its leadership in pediatric and remote surgery. As of Aug. 31, the company had completed 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries, including a record-setting telesurgery spanning more than 13,600 miles between Colombia and India. In August, five SSi Mantra systems were used to perform 50 robotic general surgery procedures in a single day in India, showcasing the system's efficiency and reliability in high-volume settings.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. The company also believes it can obtain European Union CE marking certification by year-end 2026. These regulatory milestones are critical for expanding into high-value markets and competing with established robotic surgery platforms.
The company's vision is to make robotic surgery affordable and accessible to a larger segment of the global population. Its product range includes the SSi Mantra system and the SSi Mudra suite of surgical instruments, which support a variety of procedures, including cardiac surgery. Headquartered in India, SS Innovations positions itself as an American company with a global outlook, aiming to disrupt the surgical robotics market by offering cost-effective, user-friendly solutions.
The growth in procedures and installations signals strong demand for the SSi Mantra, particularly in emerging markets where traditional robotic systems are often prohibitively expensive. By training a large network of physicians and achieving milestones in telesurgery, SS Innovations is not only expanding its footprint but also advancing the standard of care. The upcoming FDA and CE mark decisions could further accelerate adoption, opening doors to the U.S. and European markets. For investors and healthcare stakeholders, these developments indicate a company on the cusp of significant expansion, with the potential to reshape global surgical practices. For more details, visit the full report at https://ibn.fm/DJILj. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
